If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
=== Mechanism of action === Disruption of the DNA structure caused by the crosslinksobstructs the DNA polymerases, preventing DNA replication and transcription. This causes the cell to go into cell cycle arrest it cannot go on from the G2 to the M phase and stops at the G2/M checkpoint. The cell tries to repair the DNA before dividing. The intrastrand crosslinks are normally repaired by the excision repair pathway. It attempts to remove the platinum adducts. If repair fails or is insufficient, apoptosis is induced and leads to cell death. However, cancer cells have impaired apoptosis pathways limited DNA repair pathways. This can decrease the efficacy of the drug and can lead to resistance to the drug. It has been observed that radiotherapy pairs well with administration with the drug, but how this works is not entirely established. It is known that cells that cells that are stuck at the G2/M phase of the cell cycle and have impaired DNA repair system are more sensitive to radiotherapy. This suggests that nedaplatin is a radiosensitizer,
Centers for Disease Control: Obesity Data and Statistics American Obesity Treatment Association: Obesity Education and Statistics Archived February 28, 2021, at the Wayback Machine Contributors to Obesity | Tableau Public Archived January 3, 2015, at the Wayback Machine (infographic for the United States)
== I == Iatrogenic A condition unintentionally caused by medical treatment or diagnostic procedures. In neuroscience, may refer to nerve damage, seizures, or cognitive effects resulting from interventions. Ictal Relating to or occurring during a seizure or convulsion. Commonly used in the context of epilepsy, such as "ictal phase" versus "postictal phase." Imaging genetics A research field that combines brain imaging and genetics to investigate how genetic variation affects brain structure and function. Immunohistochemistry A technique that uses antibodies to detect specific proteins or antigens in tissue sections. Frequently used to visualize neuronal and glial markers. Implicit memory Unconscious memory of skills and procedures, such as riding a bike or playing an instrument. Associated with brain structures like the basal ganglia and cerebellum. Incus One of the three auditory ossicles in the middle ear that transmits sound vibrations from the malleus to the stapes. Independent component analysis (ICA) A computational method used to separate mixed signals into independent sources. Commonly used in EEG and fMRI to identify distinct brain activity patterns. Inferior colliculus A midbrain structure involved in auditory processing, particularly sound localization and reflexive responses to sound stimuli. Inferior olive A brainstem nucleus that sends climbing fiber inputs to the cerebellum and plays a critical role in motor learning and coordination.
Bard (1933–2024), American chemist known for development of the scanning electrochemical microscope, Wolf Prize in Chemistry Vincenzo Barone (born 1952), Italian chemist working in theoretical and computational chemistry Denise Barthomeuf (1934-2004), French chemist working on zeolites Neil Bartlett (1932–2008), English/Canadian/American chemist known for creating the first noble-gas compound Sir Derek Barton (1918–1998), 1969 Nobel Prize in Chemistry for “contributions to the development of the concept of conformation and its application in chemistry"
== Purification of products == In his 2016 Handbook of Synthetic Organic Chemistry, Michael Pirrung wrote that yield is one of the primary factors synthetic chemists must consider in evaluating a synthetic method or a particular transformation in "multistep syntheses." He wrote that a yield based on recovered starting material (BRSM) or (BORSM) does not provide the theoretical yield or the "100% of the amount of product calculated", that is necessary in order to take the next step in the multistep systhesis. Purification steps always lower the yield, through losses incurred during the transfer of material between reaction vessels and purification apparatus or imperfect separation of the product from impurities, which may necessitate the discarding of fractions deemed insufficiently pure. The yield of the product measured after purification (typically to >95% spectroscopic purity, or to sufficient purity to pass combustion analysis) is called the isolated yield of the reaction.
Sources: en.wikipedia.org
Hiroaki Suga (菅 裕明, born February 21, 1963) is a Japanese biochemist and businessman. He is best known for his work on artificial ribozymes (flexizymes) and their application in mRNA display (RaPID, random nonstandard peptide integrated discovery). Suga was awarded the 2023 Wolf Prize in Chemistry, jointly with Chuan He and Jeffery W. Kelly, "for pioneering discoveries that illuminate the functions and pathological dysfunctions of RNA and proteins and for creating strategies to harness the capabilities of these biopolymers in new ways to ameliorate human diseases."
He reported on the situation of the Sudeten Germans and gave details of four plans that had been proposed to deal with the crisis, each of which had points that, he reported, made it unacceptable to the other parties to the negotiations. The four plans included, first, the transfer of the Sudetenland to the Reich, second, holding a plebiscite on the transfer of the Sudetenland to the Reich, third, organising a Four-Power Conference on the matter and, fourth, creating a federal Czechoslovakia. At the meeting, he said that he was very reluctant to offer his own solution and had not seen that as his task. The most that Halifax said was that the great centres of opposition were in Eger and Asch, in the northwestern corner of Bohemia, where about 800,000 Germans and very few others lived. Halifax said that the transfer of these areas to Germany would almost certainly be a good thing adding that the Czechoslovak army would certainly oppose that very strongly and that Beneš had said that it would fight, rather than accept it. British Prime Minister Neville Chamberlain met Adolf Hitler in Berchtesgaden on 15 September and agreed to the cession of the Sudetenland. Three days later, French Prime Minister Édouard Daladier did the same. No Czechoslovak representative was invited to the discussions. Germany was now able to walk into the Sudetenland without firing a shot. Chamberlain met Hitler in Godesberg on 22 September 1938 to confirm the agreements.
The town of Billericay was established in the 13th century in the Manor and Parish of Great Burstead. The Manor of Burgestede is first recorded in an Anglo-Saxon will of 975 AD. In the Domesday Book of 1086, two separate manors are recorded as Burghestada. The name Great Burstead is first recorded in the early 13th century, but the division into Great and Little Burstead Manors had happened by the time of the Norman Conquest. The town of Billericay, first recorded as Byllyrica in 1291, is understood to have been founded in the 13th century by the Abbot of West Ham, head of the Cistercian community of Stratford Langthorne Abbey, 20 miles (32.2 km) away on the Lower Lea, in what is now inner London. The Abbey held the Manor of Great Burstead at the time. The town was established at the High Street. Like the abandoned Roman settlement just to the south, it benefitted from a prominent position on the high ground forming the watershed on the catchment areas of the rivers Crouch and Wid. It was also on the crossroads (at Sun Corner) of the road from the Thames to Chelmsford (the modern B1007) and the A129 road linking Hutton to Wickford; it is believed that the Crouch may have been navigable as far as Wickford at that time. At this time, the parish church for Billericay was at St Mary Magdalene, Great Burstead. By the 14th century, a chantry chapel had been built on the High Street, which became a chapel of ease to Great Burstead following the Reformation; it eventually became a parish church in 1844, also dedicated to St Mary Magdalen.
=== Oxidative damage === In aerobic organisms the energy needed to fuel biological functions is produced in the mitochondria via the electron transport chain. Reactive oxygen species (ROS) with the potential to cause cellular damage are produced along with the release of energy. ROS can damage lipids, DNA, RNA, and proteins, which, in theory, contributes to the physiology of aging. ROS are produced as a normal product of cellular metabolism. In particular, one major contributor to oxidative damage is hydrogen peroxide (H2O2), which is converted from superoxide that leaks from the mitochondria. Catalase and superoxide dismutase ameliorate the damaging effects of hydrogen peroxide and superoxide, respectively, by converting these compounds into oxygen and hydrogen peroxide (which is later converted to water), resulting in the production of benign molecules. However, this conversion is not 100% efficient, and residual peroxides persist in the cell. While ROS are produced as a product of normal cellular functioning, excessive amounts can cause deleterious effects.
== Further reading == Pohlschroder, Mechthild; Pfeiffer, Friedhelm; Schulze, Stefan; Halim, Mohd Farid Abdul (1 September 2018). "Archaeal cell surface biogenesis". FEMS Microbiology Reviews. 42 (5): 694–717. doi:10.1093/femsre/fuy027. PMC 6098224. PMID 29912330.
Sources: en.wikipedia.org
=== Books === Two biographies have been written about Staley, both authored by Adriana Rubio—Layne Staley: Angry Chair released in 2003, which contains an alleged final interview of Staley that Rubio claimed to have conducted less than three months before his death, and Layne Staley: Get Born Again, released in 2009, a revised and updated version of her earlier book. Staley's family has disputed Rubio's work, stating they do not believe she interviewed him in 2002. When questioned about the authenticity of the book, Rubio refused to confirm the interview was genuine. Staley's last interview was for the radio program Rockline on July 19, 1999, promoting the release of the compilation album Nothing Safe: Best of the Box with the other members of Alice in Chains. The content of Rubio's book, including what she referred to as Staley's final interview, was called into question in journalist David De Sola's 2015 book Alice in Chains: The Untold Story. De Sola questions not only the content of the interview, which portrays Staley as using his lyrics in casual conversation, it also indicates that Rubio never spoke to him, citing her refusal to release the tape with the interview and the fact that not even her publisher had access to the tape. One of Staley's sisters, Liz Coats, likewise doubted the veracity of the book. Staley was featured on the books Grunge Is Dead: The Oral History of Seattle Rock Music (2009) by Greg Prato, and Everybody Loves Our Town: An Oral History of Grunge (2011) by Mark Yarm.
== Related preservation methods == Other methods have been in place for thousands of years to halt the decomposition of the body. Mummification used by the ancient Egyptians is a widely known method which involves the removal of body fluid and wrapping the body in linens. Prior to mummification, Egyptians would lay the body in a shallow pit in the desert and allow the sun to dehydrate the body. Formalin, an important solution to body preservation, was introduced in 1896 to help with body preservation. Soon to follow formalin, color-preserving embalming solutions were developed to preserve lifelike color and flexibility to aid in the study of the body. Paraffin impregnation was introduced in 1925, and the embedding of organs in plastic was developed in the 1960s. Body preservation methods current to the 21st century are cryopreservation, which involves the cooling of the body to very low temperatures to preserve the body tissues, plastination, and embalming. Other methods used in modern times include the Silicone S 10 Standard Procedure, the Cor-Tech Room temperature procedure, the Epoxy E 12 procedure, and the Polyester P 35 (P 40) procedure. The Silicone S 10 is the procedure most often used in plastination and creates opaque, natural-looking specimen., Dow Corning Corporation's Cor-Tech Room Temperature Procedure is designed to allow plastination of specimen at room temperature to various degrees of flexibility using three combinations of polymer, crosslinker, and catalyst.
== Terminology == The name used until 2026, polycystic ovary syndrome (PCOS), derived from a typical finding on medical images called "polycystic ovary morphology". A polycystic ovary has an abnormally large number of developing follicles, looking like many small cysts. There were various objections to the name polycystic ovary syndrome: the "cysts" are not truly cysts, but arrested follicles. Having many follicles in the ovaries is also not unique to PMOS, and is often seen in women without PMOS, particularly adolescents. Furthermore, the name implied that PMOS is a gynecological condition only, rather than a metabolic and endocrine condition. Other previous names for PMOS were Stein–Leventhal syndrome and polycystic ovary disease. Suggested names included hyperandrogenic (chronic) anovulation, estrogenic ovulatory dysfunction or functional female hyperandrogenism. For specific subgroups, suggested names included multi-follicular ovarian disorder for those with polycystic ovary morphology, and metabolic hyperandrogenic syndrome for those meeting the NIH PMOS criteria. Following discussions among clinicians and people with PCOS, a majority of whom were in favour of renaming the condition, a survey was launched to find a new name. In 2026, an article by Helena Teede and others in The Lancet described the "multistep global consensus process" through which clinicians agreed to rename the condition "polyendocrine metabolic ovarian syndrome" (PMOS).
Progesterone levels in the blood were found to be lower in those who had higher weight and higher BMI among those who became pregnant through in vitro fertilization. Current data shows that micronized progesterone, which is chemically identical to the progesterone produced in the human body, in combination with estrogen in menopausal hormone therapy does not seem to have significant effects on venous thromboembolism (blood clots in veins) and ischemic stroke (lack of blood flow to the brain due to blockage of a blood vessel that supplies the brain). However, more studies need to be conducted to see whether or not micronized progesterone alone or in combined menopausal hormone therapy changes the risk of myocardial infarctions (heart attacks). There have not been any studies done yet on the effects of micronized progesterone on hair loss due to menopause. Despite suggestions for using hormone therapy to prevent loss of muscle mass in post-menopausal individuals (age 50+), menopausal hormone therapy involving either estrogen alone, or estrogen and progesterone combined, has not been found to preserve muscle mass. Menopausal hormone therapy also does not result in body weight reduction, BMI reduction, or change in glucose metabolism.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.